Welcome to our dedicated page for OCULAR THERAPEUTIX SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OCULAR THERAPEUTIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OCULAR THERAPEUTIX's regulatory disclosures and financial reporting.
Ocular Therapeutix director Leslie J. Williams received new equity awards. On June 10, 2026, Williams was granted 14,000 shares of common stock as restricted stock units under the company’s 2021 Stock Incentive Plan. These RSUs vest in full after one year of continued board service or just before the next annual stockholder meeting.
Williams was also granted options to buy 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036, with the same one-year vesting schedule tied to continued board service. After these grants, Williams directly holds 65,433 shares of common stock and 44,000 stock options.
Ocular Therapeutix reported that stockholders approved Amendment No. 5 to its 2021 Stock Incentive Plan, increasing the number of shares issuable under the plan by 10,000,000 shares. This expands the equity pool available for employee, director, and officer compensation.
The Board also appointed Jason Robins, previously interim Chief Financial Officer, as Chief Financial Officer. His annual base salary will be $535,100 from July 1, 2026, with a target cash bonus of 45% of salary. He received an option for 14,024 shares and a restricted stock unit award for 15,441 shares, subject to multi‑year vesting. Stockholders supported holding future advisory votes on executive compensation every year.
Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open-market sale of 14,828 shares of common stock at a weighted average price of $8.27 per share. The sale was made under a pre-established durable automatic sale instruction to cover tax withholding tied to restricted stock units vesting on June 1, 2026, and was not a discretionary trade. Following this transaction, she directly holds 300,079 shares of common stock.
OCUL filed a Form 144 notifying the planned sale of 14,828 common shares tied to restricted stock vesting under a registered plan. The shares are scheduled for 06/01/2026 and the filing appears on 06/03/2026 for NASDAQ trading.
The filing lists an aggregate dollar figure of $122,648.32 associated with the transaction and identifies the sale method as pursuant to a registered plan; additional proceeds treatment or holder details are not shown in the excerpt.
Ocular Therapeutix director and officer Pravin Dugel reported automatic tax‑related sales and internal share transfers. On May 26, 2026, 21,156 shares of common stock were sold at a weighted average price of $8.20 per share under a durable automatic sale instruction to cover tax withholding from restricted stock unit vesting. Following this sale, Dugel held 2,597,170 shares directly. On May 28, 2026, 394,696 shares previously held by his spouse were transferred for no consideration to the Pravin Dugel 2024 Irrevocable Trust, where he is trustee and lifetime beneficiary, leaving 694,811 shares in the trust and 0 in the spouse account while maintaining his beneficial ownership.
Ocular Therapeutix Chief Development Officer Peter Kaiser reported an open-market sale of 2,967 shares of common stock at a weighted average price of $8.20 per share on May 26, 2026, leaving him with 266,141 shares held directly.
According to the disclosure, these shares were sold under a durable automatic sale instruction adopted on April 9, 2024 to execute a sell-to-cover election for tax withholding related to restricted stock units vesting on May 22, 2026. The filing states that the sales do not represent a discretionary trade by Kaiser.
Ocular Therapeutix’s Chief Scientific Officer Jeffrey S. Heier reported an open-market sale of 3,018 shares of common stock at a weighted average price of $8.20 per share.
According to the footnotes, the sale was executed under a durable automatic sale instruction adopted on April 9, 2024 to effect a sell-to-cover election for tax withholding tied to restricted stock units vesting on May 22, 2026, and does not represent a discretionary trade. Following the transaction, Heier directly holds 320,350 shares of Ocular Therapeutix common stock.
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak reported an open-market sale of 1,858 shares of common stock on May 26, 2026 at a weighted average price of $8.20 per share. The transaction was executed under a durable automatic sale instruction to effect a sell-to-cover election for tax withholding tied to restricted stock units vesting on May 22, 2026, and was not a discretionary trade. Following this sale, Nayak directly holds 328,795 shares of Ocular Therapeutix common stock.
OCUL notice: Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell 1,858 shares of Common Stock relating to restricted stock vesting under a registered plan dated 05/22/2026. The filing lists a company reference date of 05/26/2026.
Company files a Form 144 notice to sell 2,967 shares of Common Stock. The filing states the securities are restricted stock vesting under a registered plan and lists an intended sale date of 05/22/2026. The securities are associated with trading on NASDAQ.